Status:
COMPLETED
Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Tuberculosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Anti-HIV treatment consisting of lamivudine/zidovudine (3TC/ZDV) and efavirenz (EFV) is the current standard of care for initial treatment of HIV in most areas of the world. The purpose of this study ...
Detailed Description
In many parts of the world, initial standard of care for HIV includes 3TC/ZDV and the non-nucleoside reverse transcriptase inhibitor EFV. However, it is unclear if early (CD4 count less than 350 cells...
Eligibility Criteria
Inclusion
- HIV-infected
- Received pre- and post-test counseling at the GHESKIO Centers
- CD4 count between 200 and 350 cells/mm3
- World Health Organization (WHO) Stage I, II, or III HIV disease
- Willing to use acceptable forms of contraception
Exclusion
- WHO Stage IV HIV disease (AIDS)
- 7 or more days of cumulative ART prior to study entry OR on ART at time of study entry
- Active TB, if diagnostic work-up for TB is incomplete OR if decision to treat TB has not been made. More information on this criterion can be found in the protocol.
- Recurrent active TB OR history of interrupted or incomplete TB therapy. More information on this criterion can be found in the protocol.
- Has not been evaluated for latent TB and decision to treat latent TB with isoniazid has not been made. More information on this criterion can be found in the protocol.
- Requires ART in the next 3 months, in the opinion of the investigator
- Other serious medical illness requiring chronic maintenance therapy (e.g., hypertension, diabetes) UNLESS the individual has completed at least 14 days of therapy prior to study enrollment AND is clinically stable
- Any psychological condition (e.g., severe depression, schizophrenia) that, in the opinion of the investigator, may interfere with the study
- Any social condition (e.g., pending emigration, pending incarceration) that, in the opinion of the investigator, may interfere with the study
- Active drug or alcohol use that, in the opinion of the investigator, may interfere with the study
- Current inflammation of the pancreas
- Allergy/sensitivity to any of study drugs or their formulations
- Requires certain medications
- Enrolled in another therapeutic or interventional clinical trial
- Pregnant or breastfeeding
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
816 Patients enrolled
Trial Details
Trial ID
NCT00120510
Start Date
July 1 2007
End Date
September 1 2009
Last Update
October 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Les Centres GHESKIO CIPRA CRS
Port-au-Prince, Haiti, HT-6110